divestiture

Rosetta acquired PersonalizeDx and its range of molecular diagnostic offerings in early 2015 for $2 million in cash plus stock.

Hologic's CEO said in December that the blood screening business was a drag on the company's growth. 

The company said the divestiture to Varian Medical Systems would allow it to concentrate on investing in high-growth parts of its business.

Hologic CEO Steve MacMillan said that the deal is so compelling that the firm needed to do it now.

The company said it earned approximately $128 million in revenue in 2015, and accessioned 42,000 total commercial diagnostic test samples.

The moves are part of an organizational restructuring designed to increase the company's focus on its core women's health business and reduce operating costs.

Transgenomic has completed its divestment of its Genetic Assays and Platforms unit to Adstec

PDI also said that it would assume the name of its subsidiary, Interpace Diagnostics, to better reflect its focus on its molecular diagnostic operations.

The company sold the technology and assets to Edge BioSystems as part of an ongoing effort to divest legacy non-core businesses and product lines.

NEW YORK (GenomeWeb) – Saying that it does not believe its Chemical and Applied Markets division can achieve "acceptable financial performance" in the next two years, Bruker today said that it plans to sell and/or restructure certain parts of the CAM business, resulting in an expected 200 to 250

Pages

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.